table of content
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.4 Entry and Fusion Inhibitors
1.2.5 Protease Inhibitors (PIs)
1.2.6 Integrase Inhibitors
1.2.7 Coreceptor Antagonists
1.3 Market by Application
1.3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Labs
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Perspective (2018-2030)
2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Growth Trends by Region
2.2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Region (2023-2030)
2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Dynamics
2.3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Trends
2.3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers
2.3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Challenges
2.3.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue
3.1.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue
3.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio
3.4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2022
3.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Area Served
3.6 Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
3.7 Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Type
4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Type (2023-2030)
5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Application
5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2018-2030)
6.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2018-2023)
6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2018-2030)
7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2018-2023)
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2018-2030)
8.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2018-2023)
8.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2018-2030)
9.2 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2018-2023)
9.3 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2018-2030)
10.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2018-2023)
10.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AbbVie, Inc.(U.S.)
11.1.1 AbbVie, Inc.(U.S.) Company Detail
11.1.2 AbbVie, Inc.(U.S.) Business Overview
11.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.1.4 AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2018-2023)
11.1.5 AbbVie, Inc.(U.S.) Recent Development
11.2 Merck & Co., Inc. (U.S.)
11.2.1 Merck & Co., Inc. (U.S.) Company Detail
11.2.2 Merck & Co., Inc. (U.S.) Business Overview
11.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.2.4 Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2018-2023)
11.2.5 Merck & Co., Inc. (U.S.) Recent Development
11.3 Bristol-Myers Squibb Company (U.S.)
11.3.1 Bristol-Myers Squibb Company (U.S.) Company Detail
11.3.2 Bristol-Myers Squibb Company (U.S.) Business Overview
11.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2018-2023)
11.3.5 Bristol-Myers Squibb Company (U.S.) Recent Development
11.4 Boehringer Ingelheim GmbH (Germany)
11.4.1 Boehringer Ingelheim GmbH (Germany) Company Detail
11.4.2 Boehringer Ingelheim GmbH (Germany) Business Overview
11.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.4.4 Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2018-2023)
11.4.5 Boehringer Ingelheim GmbH (Germany) Recent Development
11.5 Genentech, Inc. (U.S.)
11.5.1 Genentech, Inc. (U.S.) Company Detail
11.5.2 Genentech, Inc. (U.S.) Business Overview
11.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.5.4 Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2018-2023)
11.5.5 Genentech, Inc. (U.S.) Recent Development
11.6 Cipla, Inc. (India)
11.6.1 Cipla, Inc. (India) Company Detail
11.6.2 Cipla, Inc. (India) Business Overview
11.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.6.4 Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2018-2023)
11.6.5 Cipla, Inc. (India) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
